HL-237 is under clinical development by Hanlim Pharm and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II drugs for Rheumatoid Arthritis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HL-237’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HL-237 is under development for the treatment of rheumatoid arthritis and sicca syndrome (Sjogren). It is administered by oral route as a tablet. The drug candidate acts by targeting STAT3.
Hanlim Pharm overview
Hanlim Pharm is a healthcare company that develops, manufactures and markets prescription and non-prescription drugs. The company’s prescription drugs include osteoporosis therapeutics, emergency or shock agents, endocrine-metabolism agents, alimentary drugs, hemostatics and anticoagulants, muscle relaxants, antibiotics, allergy and ENT drugs, antineoplastic or adjuvants, CNS drugs, oliguria therapeutics and others. Its non-prescription drugs comprise vasoprotectives, iron or nutritional supplements, anti-hemorrhoids and others. The company operates its factory in Yongin, South Korea. Hanlim Pharm is headquartered in Seoul, South Korea.
For a complete picture of HL-237’s drug-specific PTSR and LoA scores, buy the report here.